EA200000921A1 - Антагонисты рецептора витронектина - Google Patents

Антагонисты рецептора витронектина

Info

Publication number
EA200000921A1
EA200000921A1 EA200000921A EA200000921A EA200000921A1 EA 200000921 A1 EA200000921 A1 EA 200000921A1 EA 200000921 A EA200000921 A EA 200000921A EA 200000921 A EA200000921 A EA 200000921A EA 200000921 A1 EA200000921 A1 EA 200000921A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vitronectin receptor
antagonists
diseases
restenosis
osteoporosis
Prior art date
Application number
EA200000921A
Other languages
English (en)
Inventor
Вилльям Х. Миллер
Джон Г. Глисон
Дирк Хирдинг
Джеймс М. Саманен
Ирен Н. Юзинскас
Питер Дж. Мэнли
Original Assignee
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн
Publication of EA200000921A1 publication Critical patent/EA200000921A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Фармацевтически активные соединения, которые подавляют рецептор витронектина и являются применимыми для лечения воспалений, раковых и сердечно-сосудистых заболеваний, таких как атеросклероз и рестеноз, а также заболеваний, фактором которых является резорбция костей, таких как остеопороз.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000921A 1998-03-10 1999-03-10 Антагонисты рецептора витронектина EA200000921A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11
PCT/US1999/005232 WO1999045927A1 (en) 1998-03-10 1999-03-10 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
EA200000921A1 true EA200000921A1 (ru) 2001-04-23

Family

ID=26759473

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000921A EA200000921A1 (ru) 1998-03-10 1999-03-10 Антагонисты рецептора витронектина

Country Status (24)

Country Link
EP (1) EP1061921A4 (ru)
JP (1) JP2002506033A (ru)
KR (1) KR20010041812A (ru)
CN (1) CN1299282A (ru)
AP (1) AP2000001898A0 (ru)
AR (1) AR015241A1 (ru)
AU (1) AU758498B2 (ru)
BG (1) BG104824A (ru)
BR (1) BR9908636A (ru)
CA (1) CA2323208A1 (ru)
CO (1) CO5080762A1 (ru)
DZ (1) DZ2741A1 (ru)
EA (1) EA200000921A1 (ru)
HU (1) HUP0101143A3 (ru)
ID (1) ID26223A (ru)
IL (1) IL138245A0 (ru)
NO (1) NO20004503L (ru)
OA (1) OA12189A (ru)
PE (1) PE20000323A1 (ru)
PL (1) PL342881A1 (ru)
SK (1) SK13292000A3 (ru)
TR (1) TR200002625T2 (ru)
UY (2) UY25421A1 (ru)
WO (1) WO1999045927A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
PE20020665A1 (es) 2000-06-15 2002-08-14 Pharmacia Corp ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
WO2005085241A1 (ja) * 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2008536918A (ja) 2005-04-20 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フッ素置換ピリジンｎ−オキサイド系トロンビンモジュレーターおよび窒素含有ヘテロアリールのｎ−オキサイド化方法
WO2015030189A1 (ja) * 2013-08-29 2015-03-05 京都薬品工業株式会社 新規芳香族化合物およびその用途
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1353897A (en) * 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997024124A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists

Also Published As

Publication number Publication date
PL342881A1 (en) 2001-07-16
EP1061921A4 (en) 2005-03-30
UY25519A1 (es) 1999-12-13
NO20004503L (no) 2000-10-10
EP1061921A1 (en) 2000-12-27
CO5080762A1 (es) 2001-09-25
KR20010041812A (ko) 2001-05-25
CN1299282A (zh) 2001-06-13
WO1999045927A1 (en) 1999-09-16
TR200002625T2 (tr) 2000-12-21
OA12189A (en) 2006-05-09
SK13292000A3 (sk) 2001-06-11
DZ2741A1 (fr) 2003-09-08
JP2002506033A (ja) 2002-02-26
CA2323208A1 (en) 1999-09-16
BR9908636A (pt) 2002-01-08
NO20004503D0 (no) 2000-09-08
IL138245A0 (en) 2001-10-31
PE20000323A1 (es) 2000-05-24
AP2000001898A0 (en) 2000-09-30
ID26223A (id) 2000-12-07
AU758498B2 (en) 2003-03-20
BG104824A (en) 2001-05-31
HUP0101143A2 (hu) 2001-08-28
AR015241A1 (es) 2001-04-18
AU2903399A (en) 1999-09-27
HUP0101143A3 (en) 2002-12-28
UY25421A1 (es) 2001-07-31

Similar Documents

Publication Publication Date Title
EA200000921A1 (ru) Антагонисты рецептора витронектина
FI920771A0 (fi) Hydroxylamidbaserade kollagenasinhibitorer.
DK1115701T3 (da) Arylsulfonanilidurinstoffer
EA200200262A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
EA200200873A1 (ru) Новые пиперазиновые производные
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
EA200000660A1 (ru) Антагонисты рецептора интегрина
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EA200300306A1 (ru) Спиропиримидин-2,4,6-трионовые ингибиторы металлопротеиназы
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
EA199900356A1 (ru) Антагонисты рецептора витронектина
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
DE69908397D1 (de) Betulinsäure derivate zur behandlung von neuroektodermalen tumoren
ES2221950T3 (es) Dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
ES2188906T3 (es) Inhibidores de la enzima de conversion de la interleucina-1beta a base de sulfonamida.
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DE69523914T2 (de) Pyridylbisphosphonate als therapeutische wirkstoffe
DE69911017D1 (en) Arylsulfonanilid-phosphate
ECSP003590A (es) Compuestos calcioliticos
TR200100363T2 (tr) Vitronektin reseptör antagonistleri.
DE69324910T2 (de) Triazolopyrimidinderivate als angiotensin-ii rezeptor antagonisten
HUP0202710A2 (hu) Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE60204014D1 (de) Chlormethylierung von thiophene